Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination cosmetic procedure involving **VI Peel**, a medium-depth chemical peel containing a proprietary blend of **trichloroacetic acid (TCA), phenol, salicylic acid, retinoic acid/tretinoin, and vitamin C**, and **botulinum toxin type A**, a neurotoxin that blocks acetylcholine release at neuromuscular junctions, resulting in temporary muscle paralysis. VI Peel induces controlled skin exfoliation and stimulates collagen, improving pigment, texture, and fine lines, while botulinum toxin type A prevents muscle contraction, reducing dynamic and static wrinkles. The combined approach targets multiple skin aging mechanisms and has been shown to be a safe and effective treatment for improving wrinkles, pigmentation, and overall skin tone with improved patient satisfaction over monotherapies[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VI Peel + botulinum toxin type A.